Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)

ClinicalTrials.gov ID: NCT03029208

Public ClinicalTrials.gov record NCT03029208. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 1:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 52-week Open-label (Sponsor-blind), Randomized, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Efficacy and Safety of Daprodustat Compared to Recombinant Human Erythropoietin in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Initiating Dialysis

Study identification

NCT ID
NCT03029208
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
312 participants

Conditions and interventions

Conditions

Interventions

  • Daprodustat Drug
  • Darbepoetin alfa Drug
  • Iron therapy Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 99 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 10, 2017
Primary completion
Sep 23, 2020
Completion
Sep 23, 2020
Last update posted
Oct 19, 2021

2017 – 2020

United States locations

U.S. sites
36
U.S. states
14
U.S. cities
34
Facility City State ZIP Site status
GSK Investigational Site Anaheim California 92801
GSK Investigational Site Cerritos California 90703
GSK Investigational Site Escondido California 92025
GSK Investigational Site Glendale California 91204
GSK Investigational Site La Palma California 90623
GSK Investigational Site Los Angeles California 90022
GSK Investigational Site Los Angeles California 90095
GSK Investigational Site Lynwood California 90262
GSK Investigational Site Sacramento California 95825
GSK Investigational Site Whittier California 90603
GSK Investigational Site Middlebury Connecticut 06762
GSK Investigational Site Coral Gables Florida 33134
GSK Investigational Site Miami Florida 33126
GSK Investigational Site Miami Florida 33169
GSK Investigational Site Augusta Georgia 30912
GSK Investigational Site Chicago Illinois 60637
GSK Investigational Site Crystal Lake Illinois 60014
GSK Investigational Site Fort Wayne Indiana 46804
GSK Investigational Site Merrillville Indiana 46410
GSK Investigational Site Michigan City Indiana 46360
GSK Investigational Site Iowa City Iowa 52242
GSK Investigational Site Baton Rouge Louisiana 70809
GSK Investigational Site New Orleans Louisiana 70112
GSK Investigational Site Baltimore Maryland 21287
GSK Investigational Site Jackson Mississippi 39216
GSK Investigational Site Kansas City Missouri 64111
GSK Investigational Site St Louis Missouri 63110
GSK Investigational Site Brooklyn New York 11203
GSK Investigational Site Buffalo New York 14215
GSK Investigational Site Mineola New York 11501
GSK Investigational Site New York New York 10029
GSK Investigational Site The Bronx New York 10461
GSK Investigational Site Houston Texas 77004
GSK Investigational Site Lufkin Texas 75904
GSK Investigational Site San Antonio Texas 78229
GSK Investigational Site Hampton Virginia 23666

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 75 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03029208, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 19, 2021 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03029208 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →